https://www.selleckchem.com/
001). On multivariable analysis, this survival difference persisted for YOPNET as an independent prognostic factor (unmatched = 0.008; matched = 0.01). For genomic analysis, patients with YOPNET had a lower rate of multiple endocrine neoplasia type-1 (MEN-1) mutation than patients with TOPNET (26% vs. 56%, 0.001). YOPNET represents a disease with distinct clinical features. Patients with YOPNET who underwent definitive surgery had better OS than patients with TOPNET despite having higher stage and tumor size. YOPNET also had lower rate of MEN-1 mutatio
Like
Comment
Share
